Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

RM Global Partners

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 5
Average round size
info
The average size of a deal this fund participated in
$41M
Portfolio companies 3
Lead investments 1
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.20
Key employees 1

Areas of investment

  • Biotechnology
  • Life Science
  • Health Care
  • Therapeutics

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of RM Global Partners:
Typical Co-investors
RM Global Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after RM Global Partners:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
212 Istanbul, Istanbul, Turkey
AAJ Capital LLC -
Arcadia Partners England, London, United Kingdom
Ez Capital Funding New York, New York, United States
First Plaza Group Trust Pennsylvania, Pittsburgh, United States
Homestead Partners California, San Francisco, United States
InvestIndustrial Holdings Luxembourg, Luxembourg
Kalamazoo Angels -
Kataweb Italy, Lazio, Rome
Kuok Ventures Central, Central Region, Singapore
M2O California, Los Angeles, United States
Mezzanine Capital Partners California, San Francisco, United States
Pioneer Venture Partners Kirkland, United States, Washington
Prime Mont V.C Beijing, Beijing, China
ProSieben Bayern, Germany, Munich
Social Alpha Bangalore, India, Karnataka
SV Investment Corp Seoul, Seoul-t'ukpyolsi, South Korea
the Honeywell pension -
Wainbridge Capital England, London, United Kingdom
XIM California, San Francisco, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

ImmPACT Bio USA

Biotechnology
Life Science
$139M20 Jan 2022 California, United States

ImmPACT Bio USA

Biotechnology
Life Science
$18M18 Aug 2020 California, United States

BIOMx

Biotechnology
Health Care
Therapeutics
$32M20 Feb 2019 Israel, North District, Israel

Mitoconix Bio

Biotechnology
Health Care
Life Science
$20M27 Jun 2017 Jerusalem, Jerusalem District, Israel

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent RM Global Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 5
Average round size 41M
Peak activity year 2020
Lead investments 1
Follow on index 0.20
Group Appearance index 1.00

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

ImmPACT Bio USA

Biotechnology
Life Science
$139M20 Jan 2022 California, United States

ImmPACT Bio USA

Biotechnology
Life Science
$18M18 Aug 2020 California, United States

BIOMx

Biotechnology
Health Care
Therapeutics
$32M20 Feb 2019 Israel, North District, Israel

Mitoconix Bio

Biotechnology
Health Care
Life Science
$20M27 Jun 2017 Jerusalem, Jerusalem District, Israel
Crunchbase icon

Content report

The following text will be sent to our editors: